The FDA have granted a first of its kind indication for Xywav for the treatment of idiopathic hypersomnia (IH) in adults.
List view / Grid view
EU marketing authorisation has been given to Sunosi (solriamfetol) for excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea.
The EMA CHMP has revealed its suggestion to grant marketing authorisation to seven medicines after its most recent meeting.
The FDA has given the XWL-008 compound Orphan Drug Designation for the treatment of narcolepsy.